Newron Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS) and pain.
Newron Pharmaceuticals – innovative therapies for Central Nervous System
Newron is a leader in the development of innovative therapies for Central Nervous System (CNS) disorders and pain and is committed to improving the quality of life of patients around the world. Newron has built a well-balanced pipeline of innovative CNS and pain treatments, including safinamide for Parkinson’s disease, licensed to Zambon Group and Meiji Seika Pharma, for which CHMP has recommended approval in the EU and filing submitted to FDA and Swissmedic. Newron’s additional projects are based on highly promising treatments for rare disease patients and are at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing NW-3509 as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.
Founded in 1999, Newron Pharmaceuticals is a biopharma company headquartered in Bresso (Italy), with fully owned clinical development subsidiaries in Stockholm (Sweden) and Basel (Switzerland). Its team has a proven track record of bringing drugs to market in these areas and has built a well-balanced pipeline that embodies highly innovative compounds at different stages of development. Management Team is composed by Stefan Weber, Ravi Anand, Marco Caremi, Roberto Galli and Anders Haegerstrand. The Company is listed on the SIX Swiss Exchange, trading symbol NWRN.
More about Newron Pharmaceuticals : www.newron.com